-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 QT3+YUaFgWIr1IYZtKaKYYgp6C1oRRrq5QZ0J7MEnsfSB4cFotTWBkpi2yjfOm4H
 jr7F7tD7oNWDpIg+POYUFQ==

<SEC-DOCUMENT>0000950124-04-003466.txt : 20040729
<SEC-HEADER>0000950124-04-003466.hdr.sgml : 20040729
<ACCEPTANCE-DATETIME>20040729093108
ACCESSION NUMBER:		0000950124-04-003466
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20040729
ITEM INFORMATION:		
ITEM INFORMATION:		Financial statements and exhibits
FILED AS OF DATE:		20040729

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TARGETED GENETICS CORP /WA/
		CENTRAL INDEX KEY:			0000921114
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				911549568
		STATE OF INCORPORATION:			WA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23930
		FILM NUMBER:		04937538

	BUSINESS ADDRESS:	
		STREET 1:		1100 OLIVE WAY
		STREET 2:		STE 100
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98101
		BUSINESS PHONE:		2066237612

	MAIL ADDRESS:	
		STREET 1:		1100 OLIVE WAY
		STREET 2:		STE 100
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98101
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v00673e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>


<P align="center" style="font-size: 10pt"><B>CURRENT REPORT</B>



<P align="center" style="font-size: 10pt"><B>Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">

<!-- Begin Table Head --><TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="58%">&nbsp;</TD>
</TR>

<!-- End Table Head -->

<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date of Report (Date of earliest event reported)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">July&nbsp;29, 2004</TD>
</TR>

<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade>&nbsp;</TD>
</TR>


<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 24pt"><B>Targeted Genetics Corporation</B>

<DIV align="center" style="font-size: 10pt"><HR size="1" noshade width="100%">
(Exact name of registrant as specified in charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">

<!-- Begin Table Head --><TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>

<!-- End Table Head -->

<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">Washington
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">0-23930
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">91-1549568</TD>
</TR>

<TR style="font-size: 1px">
    <TD colspan="5" valign="top" align="left"><HR size="1" noshade>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction<BR>
of incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission<BR>
File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(IRS Employer<BR>
Identification No.)</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">1100 Olive Way, Suite&nbsp;100, Seattle, Washington</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">98101</TD>
</TR>

<TR style="font-size: 1px">
    <TD colspan="5" valign="top" align="left"><HR size="1" noshade>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">(Address of principal executive offices)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Zip Code)</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">

<!-- Begin Table Head --><TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="58%">&nbsp;</TD>
</TR>

<!-- End Table Head -->

<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Registrant&#146;s telephone number, including area code
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(206) 623-7612</TD>
</TR>

<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade>&nbsp;</TD>
</TR>


<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">Not Applicable


<DIV align="center" style="font-size: 10pt"><HR size="1" noshade width="100%">
(Former name or former address, if changed since last report)</DIV>



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD></TD><TD colspan="8"><A HREF="#000">Item&nbsp;7. Exhibits.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#001">Item&nbsp;12. Results and Operations of Financial Condition.</A></TD></TR>
<TR><TD colspan="9"><A HREF="#002">SIGNATURES</A></TD></TR>
<TR><TD colspan="9"><A HREF="#003">EXHIBIT INDEX</A></TD></TR>
<TR><TD colspan="9"><A HREF="v00673exv99w1.htm">EXHIBIT 99.1</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>




<!-- link2 "Item&nbsp;7. Exhibits." -->
<DIV align="left"><A NAME="000"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;7. Exhibits.</B>


<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Financial statements of business acquired.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Not applicable.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pro forma financial information.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Not applicable.</TD>
</TR>

</TABLE>


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Exhibits.

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="65%">

<!-- Begin Table Head --><TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="87%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Exhibit</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>&nbsp;</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>No.</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Description</B><HR size="1" noshade></TD>
</TR>


<!-- End Table Head -->

<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release of Targeted Genetics Corporation dated July&nbsp;29, 2004</TD>
</TR>


<!-- End Table Body -->
</TABLE>
</DIV>


<!-- link2 "Item&nbsp;12. Results and Operations of Financial Condition." -->
<DIV align="left"><A NAME="001"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;12. Results and Operations of Financial Condition.</B>


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On July&nbsp;29, 2004, Targeted Genetics Corporation issued a press release
announcing its financial results for the quarter ended June&nbsp;30, 2004. A copy of
the press release is furnished as Exhibit&nbsp;99.1 and is incorporated into this
current report by reference.

<!-- link1 "SIGNATURES" -->
<DIV align="left"><A NAME="002"></A></DIV>

<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">

<!-- Begin Table Head --><TR valign="bottom">
    <TD width="58%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
</TR>

<!-- End Table Head -->

<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TARGETED
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">GENETICS CORPORATION</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date: July&nbsp;29, 2004
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Todd E. Simpson</TD>
</TR>

<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><HR size="1" noshade>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Todd E. Simpson</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vice President, Finance and Administration and Chief
Financial Officer, Secretary and Treasurer (Principal
Financial and Accounting Officer)</TD>
</TR>


<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- link1 "EXHIBIT INDEX" -->
<DIV align="left"><A NAME="003"></A></DIV>

<P align="center" style="font-size: 10pt">EXHIBIT INDEX


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="65%">

<!-- Begin Table Head --><TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="87%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Exhibit</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>&nbsp;</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>No.</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Description</B><HR size="1" noshade></TD>
</TR>


<!-- End Table Head -->

<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release of Targeted Genetics Corporation dated July&nbsp;29, 2004</TD>
</TR>


<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v00673exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="right" style="font-size: 10pt"><B>Exhibit&nbsp;99. 1</B>


<P align="center" style="font-size: 10pt"><IMG src="v00673v0067300.gif" alt="(TARGETED GENETICS LOGO)">&#169;



<P align="left" style="font-size: 10pt"><B>Contact</B><BR>
Courtney Self<BR>
Targeted Genetics<BR>
206.521.7392


<P align="center" style="font-size: 10pt"><B>TARGETED GENETICS REPORTS SECOND QUARTER 2004<BR>
FINANCIAL RESULTS</B>



<P align="center" style="font-size: 10pt"><B><I>- Clinical Progress Highlights Quarter -</I></B>


<P align="left" style="font-size: 10pt"><B>Seattle, WA </B>&#150; July&nbsp;29, 2004 &#150; Targeted Genetics Corporation (NASDAQ: TGEN)
today announced its financial results for the second quarter of 2004. As
previously announced, the Company will hold a conference call with analysts at
10:30 AM EDT today. The call will be broadcast live over the Internet and can
be accessed, along with replay information, at www.targetedgenetics.com.


<P align="left" style="font-size: 10pt">For the second quarter of 2004, the Company reported a net loss of $4.5
million, or $0.05 per share, compared to $6.9&nbsp;million, or $0.13 per share for
the second quarter of 2003. For the six months ended June&nbsp;30, 2004, the
Company reported a net loss of $9.3&nbsp;million, or $0.12 per share, compared to
$7.7&nbsp;million, or $0.15 per share for the same period in 2003.


<P align="left" style="font-size: 10pt">Revenue for the three months ended June&nbsp;30, 2004 increased to $2.8&nbsp;million
compared to $2.1&nbsp;million for the second quarter of 2003, and was $4.1&nbsp;million
for the six months ended June&nbsp;30, 2004, compared to $7.7&nbsp;million for the same
period in 2003. 2004 revenue reflects research and

<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt">development activities under Targeted Genetics&#146; AIDS vaccine collaboration with
the International AIDS Vaccine Initiative (IAVI)&nbsp;and revenue from completing
its contract manufacturing agreement with GenVec.


<P align="left" style="font-size: 10pt">&#147;Progress in our three clinical development programs continues to be a top
priority for us, and we made significant progress during the quarter. The
successful completion of an interim analysis for Targeted Genetics&#146; Phase IIb
cystic fibrosis clinical trial was a key highlight for the Company,&#148; said H.
Stewart Parker, president and chief executive officer of Targeted Genetics.
&#147;This analysis, conducted by an independent data monitoring committee, led to
their recommendation that we continue the trial as planned. We remain on
target to complete enrollment in both our cystic fibrosis and AIDS vaccine
clinical trials in 2004, while continuing to enroll patients in our rheumatoid
arthritis clinical trial, which began during the first quarter of 2004. Our
cash position remains healthy, providing us with the necessary resources to
support plans for the next stages of product development.&#148;


<P align="left" style="font-size: 10pt">Operating expenses were $7.1&nbsp;million for the second quarter of 2004, down from
$8.7&nbsp;million for the second quarter of 2003, and were $13.3&nbsp;million for the six
months ended June&nbsp;30, 2004, down from $14.8&nbsp;million for the same period in
2003. 2004 expenses reflect increased research and development expenses,
primarily attributable to the Company&#146;s AIDS vaccine and rheumatoid arthritis
programs and higher general and administrative expenses, reflecting increases
in patent issuances and regulatory compliance costs. 2003 expenses included
restructuring charges of $2.9&nbsp;million for the three months and $3.2&nbsp;million for
the six months ended June&nbsp;30, 2003, compared to $.2&nbsp;million and $.4&nbsp;million for
the same periods in 2004.


<P align="left" style="font-size: 10pt">Second quarter highlights include:



<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Successful interim analysis from the Company&#146;s cystic fibrosis
Phase IIb clinical trial; trial on track for completion by year-end;</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Targeted Genetics&#146; AAV technology highlighted in 12 presentations
at the 7th Annual Meeting of the American Society of Gene Therapy;</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Presentation of positive preclinical data from the Company&#146;s
rheumatoid arthritis program at ASGT, demonstrating complete
suppression of disease during study after intramuscular injection;</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Issuance of additional patent giving Targeted Genetics exclusive
rights to AAV1, providing expanded potential for future product
development and partnering opportunities;</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Announcement of merger agreement between CellExSys and Chromos
Molecular Systems; and</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Issuance of an exclusive worldwide license agreement with the
National Institutes of Health (NIH)&nbsp;for patents that cover ITR
(inverted terminal repeat) sequences as a promoter for use with AAV in
any product indication.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>

<P align="left" style="font-size: 10pt">Targeted Genetics develops gene-based products for preventing and treating
acquired and inherited diseases. The Company has three clinical product
development programs, targeting cystic fibrosis, AIDS prophylaxis and
rheumatoid arthritis. The Company also has a promising pipeline of product
candidates focused on hemophilia and cancer and a broad platform of gene
delivery technologies. For more information about the Company visit its website
at www.targetedgenetics.com.


<P align="left" style="font-size: 10pt"><I>NOTE: This release contains forward-looking statements regarding our projected
financial resources, intellectual property, clinical trials and regulatory
filings and anticipated data from our clinical and preclinical programs. These
statements, involve current expectations, forecasts of future events and other
statements that are not historical facts. Inaccurate assumptions and known and
unknown risks and uncertainties can affect the accuracy of forward-looking
statements. Actual results could differ materially from expectations for a
number of reasons, including failure of our partners to provide funding, our
failure to make progress with our clinical trials, our failure to obtain
positive results from our preclinical programs, our failure to obtain or
maintain regulatory approvals, our failure to maintain or protect our
intellectual property and the other risks described in the section entitled
&#147;Factors Affecting Our Operating Results, Our Business and Our Stock Price&#148; in
our Quarterly Report on Form 10-Q for the quarter ended March&nbsp;31, 2004. You
should not rely unduly on these forward-looking statements, which apply only as
of the date of this release. We undertake no duty to publicly announce or
report revisions to these statements as new information becomes available that
may change our expectation.</I>



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<P align="center" style="font-size: 10pt"><B>TARGETED GENETICS CORPORATION</B><BR>
<I>(in thousands, except per share information)</I><BR>
(unaudited)


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="95%">

<!-- Begin Table Head --><TR valign="bottom">
    <TD width="56%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7"><B>Three months ended</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7"><B>Six months ended</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7"><B>June 30,</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7"><B>June 30,</B><HR size="1" noshade></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>2004</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>2003</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>2004</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>2003</B><HR size="1" noshade></TD>
</TR>


<!-- End Table Head -->

<!-- Begin Table Body -->
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><B>Statement of Operations Information:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Collaborative agreements with affiliates</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">2,761</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">2,053</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">4,081</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">7,692</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Operating expenses:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Research &#038; development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,828</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,327</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,065</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,869</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:20px; text-indent:-10px">General &#038; administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,066</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,438</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,816</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,774</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Restructure charges</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">221</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,899</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">416</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,180</TD>
    <TD>&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Total operating expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7,115</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,664</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13,297</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14,823</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Loss from operations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(4,354</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(6,611</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(9,216</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(7,131</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Investment income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">56</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">145</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">108</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Interest expense</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(117</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(360</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(237</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">(722</TD>
    <TD nowrap>)</TD>
</TR>

<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Net loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">4,450</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(6,915</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(9,308</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(7,745</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Net loss per common share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(0.05</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(0.13</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(0.12</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(0.15</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Shares used in computation of net loss
per common share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">81,604</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">51,694</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">77,239</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">51,133</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>


<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="center" style="font-size: 10pt"><B>TARGETED GENETICS CORPORATION</B><BR>
(<I>in thousands)</I>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="65%">

<!-- Begin Table Head --><TR valign="bottom">
    <TD width="74%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>December 31,</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>2004</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>2003</B><HR size="1" noshade></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" colspan="3"><B>(unaudited)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>


<!-- End Table Head -->

<!-- Begin Table Body -->
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><B>Balance Sheet Information:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">37,381</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">21,057</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Other current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">554</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">575</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Property and equipment, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,876</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,423</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Other assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32,462</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32,617</TD>
    <TD>&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Total assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">73,273</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">57,672</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">8,328</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">6,709</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Long-term obligations and other liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16,231</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16,734</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Preferred stock and minority interest</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">750</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Shareholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">48,714</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33,479</TD>
    <TD>&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Total liabilities and shareholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">73,273</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">57,672</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>


<!-- End Table Body -->
</TABLE>
</DIV>




<P align="center" style="font-size: 10pt">&nbsp;
</DIV>


</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>v00673v0067300.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v00673v0067300.gif
M1TE&.#EAB@"\`/<```!:2@!C2@!C4@!K4@!K6@!S6@!S8P![8P![:P"$:PA[
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M_____________________RP`````B@"\```(_@#_"!Q(L*#!@P@3*ES(L*'#
MAQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DR@17F'BA*7+EC!?RHQ)<Z;-
MFCAOZLS)<Z?/GD!EKE"S1@U1HT6/*DW*%*G3I4^;0ITJM6K4JU2Q6LW*U6J<
M#S92BAVKD$58LFC3KCB;MFW*M6[CGH3KL,\1*7CS3MDQ1Z[?A'0=4A!`@("!
M`@0&!(ACD`]2A&[41&Y39^$=-6WL'*R39DV;R$8+TBD3N709Q@332);<QDQE
M@G16O]$<,3!#/CJF9+%A@$*6+"S>--Y@(`1")@8.'%:PX;7!'PT.,U@A1C0$
MY08,$!A1,,N`[`BR_@]H4O!(]O,%JA,T$SY[@Q"T'=I^Z&6[0CKA%R!,8V##
MD2,C$+#!02<,0`%>%PR@'D$;'"#$$4,(X41!9=APQ`H%D,"$#5D4)(8!'_PW
MQ`]J%&2'`P[\]P$!"_#QT'P.94$`"`I=0<`)Z1UDA@$_#.0``@:9(>!`<9!G
MT`5`,N3%`%(@%$8!1RADQP(#"O0#`3W*QQ9$611`8T+$Q5'`E@.9,28?>UQA
MP`,&V3"`%W^X""8"89B1!1T):3$`$TX:,)08<!I4AP-5_K&'`(4R!&-#,AJ'
MT!P%]'C=064@4`!A!2!@AD$%YO$'"R,(\4.4!1$G0``$N)&0C'P>%,8!_@2<
MRIU!4R8Z``1R*DIFC`0X>A`38V9A`0$+EMD?$0\8D,9!*!!0(@P'P`J#01L@
MH`8=7L1G$*M]VD`''%ILQD"A?!!@P8N[,MHKF`8@@,`"!I@0I`$Z_'&%`"P<
ME(4`*_Q161@$[$!MD@MY-Z&K!`@A)94#73'`M%I.U"A"=A!PEA\/,*#M'SO6
M^T>RJAKD0`$GN/&&"01`S"`"91BEQA5['*1GJP:%80`,H(D1AHD,4*!&&CMD
MAV?$$ATQP`-^'/1#`#L+!(,`5G0G`,3W?K"9!0,,0)@#)1*TQP,%:*UU`3$;
M=$0`66Y;6-:GDAD'K%H3<,"FZ$YD1AIBE%V0_AEFH/9'470/]'.@<N"M=T%O
M2#%%R`7)T3)1JDEQN.!\)UWSST>%$2B19KC,>-U_A>[1HJ*73A'IIJ<.ND-\
MM.[ZZ[#'+OOLM-=N^^VXW]X'1*C73($-,,0@0_##"T_\\<8G7_SRR#.O?//0
M/R^]\]1'7[T-_JW.D)VJD^5&DT0W%,85W8]E!O@-];XW^N6?E,;!Z:>+$!E3
MM)_2^]HO=+[]*.$?/D-D(-]'RG"%+!3P@`9,(`(7J$`#BL5_\7O(&*+6$3R\
MH``%T,YA-FB8#&:P@QS<8`8'<(*4[.]_"Z%?1Z1@&'>Y\(4PC*$,P\,F]\%/
M5P\YH4;HD!WE1"LY_LGQH0^#",0?"I&(#Q@:272(0X<$D"-"V$`(0##%*E:1
MBE2\HA:UB,40;.`$DP,)!)O8D`GR[R1,7(CZ"*+",Y9DC&J4GX[8Y\:0P%$A
M:QS($S62!C.4@6]__*,?!SE(0082D(0\9"$1^4>_;>2.@)&C0<R($3[4X``*
M6$`F-[E)3792`9\,I28].4I0EO(`#X!#1]*(1TD6I(T7L4`#'D"!"41@`A1X
M`"YO:4M<ZI("M\SE+B?02V$"TY?#[.4#&M`U/MXPCCFD(T68H(`'6/.:#XC`
M-;6Y36QFLYO@#"<WE_F`96F$E9%\R!XO8H<1F."=[GRG">()3WG.TY[T_KRG
M///)3WA^8&,502="\B@02G;$<@1!Z!\4RM"$.G0@"MU=KBX"R8&ZDHWUJ^-(
M*GH0@G),FAKM"$<-XM%U9H0/;8@#'%3*TI6ZM*4P?:E,8TI3F4YT(B,MB$<-
MJA$:3"`#&=!`4(<JU*(2]:A&32I2ERK4"HB`"F%\2$X)4M*,;H0/(NA`"40@
M@JUVE:M>#2M8Q_K5LHK5K&/U:@6:AM-GMC*:'DE#!SJ0U;K2=:Y9O:M>\\I7
MO/IUKW^U:P4`*E6WIM.)`NS('%1`@QF\P+$S:"P-7-#8QTZVLI&E+&0ONUG-
M6M:SD9V!"BPRU8'LE((>>5T?5-NZU?+!M;!M_JUL7SO;V-+6=;NK2&D%4M60
MBF2W?_"H0'V;$>"6-+$F00,6NL#<YCKWN="-+G2Q8$[=&M:B$D2M2?S0@A2H
MP+O@_:YXPTO>\9HWO"7``D6OV]&+ZM&J)[$##5HP@QG0M[[WM6]]]8O?_>;W
MOS,H01O6FS^%#%<D<%!!"Q;,X`8[^,$09G`*EH`1X[I7("9%21MNT(,>X*`'
M/NAPB$$LX@^/^,0E!C$.H%!<]I+TPG_@:4KVL`<TU9C&-LXQCG=\XQZCR9D%
M3@@LB2M2%^L4Q@<FLG6#/#_D_@5-N8LJ:8U,51C+V"]\\,$,;G`#&G"9RUX&
M<PO8L$J08M>)\`T=_A^*`&(@M+D';O:!FZD05RJ;%LEFELN:.8SB$0-!RE-F
M\D$R7#HH/,'04$#T$Y;@R$?:F;=6UJZ2SYGG%ZLSS9.N\*.#B^=,<\3"ZG2R
MIRV2Y"IG=]24%K1!AHSJ):/0P)5NM4-`C5C3V0$.<XC#''"M:U[O.M>_GH-"
M71U!AUPY+F%(0A&6701E,[O9SX9V$;B0D5+?^=*A@\,3BJ`$)3S!V^#^MKC#
MW6TE)`$+-Y4(K1MB[9-P@=OFCK>\D]!M>L?;WMTN0A72#9%U`U#49+%#%:B`
MA8(;_.`(3_C!J="%0+\Z(<<>R[`ODEN*^#N%F)9U1"X.:XT[O-@-(31*_OA@
MAY*;_.0H3[G*4<YOA[2;TZ<FRQRX0`4J#-SF-;^YSG/.<YS[_.94(`.QR0C`
MC).$#V&H@L*7SG2F!WWHT'1YK#\R!RP0W.I-S_K2:UY=NTW]VK4^"1^4^X6R
MF_T+73A[VLV^]K*W'>UJ_P(9//5QHB\DXB#Q@XM<)-$X_:'O>_<[WP5/>+ZW
M?..;[JW'+9[X3B^^K:I^)<`]4F,H5_[&K<.\Y3,/Y<UO7@\;>?EI1X+2LYO^
M]*A//>H'#.2'S\_H.R2#W,E`^]K;_O:XSSWNO]`71T=^/5^?"!_8\`4PR)X,
MQI>[W)-_?.8O__C/5S[R9=_[T`<?YF%7+!G0_K!]-'#?^]_W?O?#3_[QFQ_\
M9*B^[UU_$+Q;1+9Z7VV<5AO_O=.?MO/G@][S+U'\U_GW[_5XD,=^07)]`C@0
M'"=DD_<0>I<[#B@[@/81"8@0[K<08U=S/]=S.Y>!'+B!-4=8=M1XV#81>H!U
M6G>"35<%=&=#`"@0+U<0?&!P5U=P,VB"-FB#-3B#!,<%$T<2$SAH"PA`7,`%
M7<`%6$"$0VB$13B$2ZB$2=B$R_6$7/`%AR<2HA=I%>$ZE:>%KL5YL[6%:-*%
MG=>#;R2":':`B->"'X6&_6:&(1>$#=%YN=,^5QAS%H$%W$9O>:@$>[AL2U"%
M?O&#JP9[$/%MW6:(_DO0;8F8!%!E/X*X/B=EB/AV;^K%/W68?>SD;4^PB8>V
MB97(/X]($!4($7N@!WN0!Z=XBJ#G1I<8<H3(A@41BF5B@&@HBQ@&A[`XBVHX
MBKFXA@3X2J_8BW]@B[XHC`E!C"*7A?NG?WNWC,YH?W_1B@S!BPZA!D`0!->(
MC=JXC=>8C=ZH!("(1M>G>!BQ87#V9D`08ND(9^K8CB06!.%8AFKX@@G1!FTF
M9_@8!'(&9^F(C?DH9W'V!'$AC2F$BP#4`F%V`UO&90NID`SYD!!I7T40C[_E
MAM,H:22(BGE@BJBH!QWYD:4(DAY9BAQ)D2%!D`K!:L88BQ:I/[1X@,AH_I"Y
MB)(0AY$/X08M`&9=II-AYF4]N9,[^9-""68S@`,@^'^_B%$4H0<XP&#VU0(N
M0%\+%I5/2953*950B956F95/B0,F67=1QVXO*1!ZP%_W)97]=99FN99JV99/
M&03RF)1Z)),'T08ED`(MH&!XF9?=M6!ZZ9=]R9=[^9>""9AX60)%L$3CB(45
MD04(9P4'!YD&)YD%1YE88)F8&9E6IT1BU)(I&8R]2(ST").>J8`KF1`T28$V
M"1%Q4`(FX%TJ$)NP*9NQ29NU.9OB=9NUF9NV29LMX!R:IH8J*1%9D`%V=9QW
MA9S*F9S,N9S*&8%M.(]C:1!+H`'.V9S8>9W:_LF<)7"4$)&:0*@115`">:E@
MYLF7YYF>Z+F>ZMF>Z!F;):`"T-D0Q$B-#.$'=C"2&XF*^:F1(]F?JLB?^OF?
M`RJ@_JF1=C"?#(&,H)F+HCF=BQ>3IXD0X#E)JWD17F`!'S`"&]JA'/JA'AJB
M(#JB(EJB(+H""GH0#`H2(S!+WO2B,!JC,CJC!]!UT2F7+@BA%F@!#O!-VG1+
M/YI-MN2C0_JC12JD00JD1+I,&]!HA26<="D1:S`!%E"E5GJE6)JE6KJE6SHK
MC+>+%YH1=E`'=%`'9'JF9&H'97JF:HJF9;JF=-"F;/JF9DJG!(:C?S"<$_J@
M$ZJBI=EDI<,'=[!Y_IA7J):W!V28AGAJGRAA!Q+0+C,T0P:@HPCXIX/6H&(A
M!@.```?`J>[2J9WJJ:%Z``6P:0K!IZ:C`Y`:JI[ZJ:YZ``ZP@J2VF*&6.GQ`
M`9$:0P90+&#Y5L86IFZQ!VX0!\3Z!L1:K,<:!\-J?<*)J6PHFL`JC&I@J08A
M!DW`!WC`D7MP!Z5XBMG:K0EJBGJ`!QVYK:DXKMK*K1SYK:88KJ5(KMW*K1WY
MK:BHKMXJKGO@KN-:KO+ZKNG:K:@8!M1:$'!@%CE@`PA;`SJ0L#:PL#6`L#KP
ML`A[L`F[L#;PL`X+L1)K`Q1[L1:+L1>KL0C+L2.KL`R;L0V[L1UKLB&+_K(1
M.[(ZP`)L97=].A(>5;,8<;,X:Q$ZN[.G`V-$$@(.H``2(`3<ZK.^^A!.@!B&
M,0"&\3D+Q1(P(04U@`<&L1).`'IV@`1,L#%\(`5.`!-.\`.-1@<2X@1@ZP1'
MH#`%X05'0`0@:`<[``,_(&5[(`0P4`-1BGT.41\&$"BWFC8$(07?<1X#`%!.
MD!AT4Q@'X3#GD1U0ZP;HD1U>8A!BDB@$`0-.BP!9P[8$\08$4`"XJC50F[0-
M,0*1,K@(,04#<`1[$*=OD&Y9D!U5HAP'804$0`1Z4`=V\`:K.!!UH`9VL",G
M4'(S*Q!OXZ4$82,7$*=GP`#J)Q#-LC-\8`,Q_L`[,,8'[<(8G'F[!-`A"C&[
M#D``36*[5TL`!ODV_8(0R7L0%&``?A,X#((EKY&BD/80>W`TFM$$#``"'[`!
M`E,04R"Z(+`!@KN\!.`%[?('EM*X!C`!(7`!!TRP?I(0[6L0!$`!%=<GAJ$`
M+%"ZIKL0>\`B>,($A`$K3FH%AT$``2`_WM$&1$``1Q`>#HP8`E`#"O$&%<R^
M!Z"\`R$`%)"H1/(#%%`8!G"\(;P0[\LG:K`["=*]?\"ZX>)WC3L`F_*^-'R^
MT?H'<;##!W'!!:$`"!`?PK$0P'(!:O@'4I!!=$,'$)`J!H&[VB6[`U`&?Z#`
MYEL0N,L^9`@'7FRY_CU\$#9``#@L$!3`>I_KN70P)'@J$`%"`!)0+88AOP)A
M(QBP`BMP`B,@3=YAQY]R&/I"`!>`R2NP`6;6Q>O[Q8%L$'G`N1^@`Q`P`!)@
M$",P`!L0LYR[.32K)!>`(A2`H@<!`RCB``S0``A`*@1A`P<`/EG@``L01C8P
MS`S@``:`S-V1`!\@95+@`!#PNP2!!RM`S!-@S0*Q!V'``A"P`(3"JV$9$24'
M:'%J!W=@<L`I$"5GM892<C>%G_),SR`XS_5,$"8':/-<A?EZ!Q+1LTA;&T"[
MT`G=T`[-.S5P>9Q'T19=T1CM>9JWT9W'T1>MT1T=TA_MT1E-TB`]TE#V20<H
M`#PQ4`,P,#PU4#PLS=(P+=/'$]/!0]-Y:],QH-,XW=,WS=,UG=-$;3P_[=-"
<O=-%C=1%/=1`;=0\#3PVX,,17=56?9H!`0``.S\_
`
end

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
